Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

mTOR in Human Diseases.

Dormond O.

Int J Mol Sci. 2019 May 11;20(9). pii: E2351. doi: 10.3390/ijms20092351.

2.

Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma.

Zoetemelk M, Rausch M, Colin DJ, Dormond O, Nowak-Sliwinska P.

Sci Rep. 2019 May 8;9(1):7103. doi: 10.1038/s41598-019-42836-0.

3.

Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.

Faes S, Santoro T, Troquier L, De Souza Silva O, Dormond O.

Biochem Biophys Res Commun. 2019 Jun 4;513(3):546-552. doi: 10.1016/j.bbrc.2019.04.044. Epub 2019 Apr 10.

PMID:
30981504
4.

Hypermobile Ehlers-Danlos-like syndrome in Fabry disease.

Barbey F, Lidove O, Dormond O.

Clin Genet. 2019 May;95(5):627-628. doi: 10.1111/cge.13497. Epub 2019 Jan 15. No abstract available.

PMID:
30644091
5.

mTOR and Tumor Cachexia.

Duval AP, Jeanneret C, Santoro T, Dormond O.

Int J Mol Sci. 2018 Jul 30;19(8). pii: E2225. doi: 10.3390/ijms19082225. Review.

6.

Ascending aortic remodelling in Fabry disease after long-term enzyme replacement therapy.

Monney P, Qanadli SD, Hajdu S, Tran C, Schwitter J, Dormond O, Barbey F.

Swiss Med Wkly. 2017 Nov 9;147:w14517. doi: 10.4414/smw.2017.14517. eCollection 2017.

7.

Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.

Faes S, Santoro T, Demartines N, Dormond O.

Cancers (Basel). 2017 Nov 1;9(11). pii: E152. doi: 10.3390/cancers9110152. Review.

8.

Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study.

Franzen DP, Nowak A, Haile SR, Mottet D, Bonani M, Dormond O, Kohler M, Krayenbuehl PA, Barbey F.

PLoS One. 2017 Jul 25;12(7):e0180437. doi: 10.1371/journal.pone.0180437. eCollection 2017.

9.

Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.

Uldry E, Faes S, Demartines N, Dormond O.

Int J Mol Sci. 2017 Jun 30;18(7). pii: E1401. doi: 10.3390/ijms18071401. Review.

10.

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.

Faes S, Demartines N, Dormond O.

Oxid Med Cell Longev. 2017;2017:1726078. doi: 10.1155/2017/1726078. Epub 2017 Feb 9. Review.

11.

Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.

Faes S, Duval AP, Planche A, Uldry E, Santoro T, Pythoud C, Stehle JC, Horlbeck J, Letovanec I, Riggi N, Demartines N, Dormond O.

Mol Cancer. 2016 Dec 5;15(1):78.

12.

Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies.

Faes S, Uldry E, Planche A, Santoro T, Pythoud C, Demartines N, Dormond O.

Oncotarget. 2016 Dec 27;7(52):86026-86038. doi: 10.18632/oncotarget.13323.

13.

Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.

Faes S, Planche A, Uldry E, Santoro T, Pythoud C, Stehle JC, Horlbeck J, Letovanec I, Riggi N, Datta D, Demartines N, Dormond O.

Oncotarget. 2016 Jun 14;7(24):36666-36680. doi: 10.18632/oncotarget.9134.

14.

Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells.

Scholz G, Jandus C, Zhang L, Grandclément C, Lopez-Mejia IC, Soneson C, Delorenzi M, Fajas L, Held W, Dormond O, Romero P.

EBioMedicine. 2016 Jan 16;4:50-61. doi: 10.1016/j.ebiom.2016.01.019. eCollection 2016 Feb.

15.

Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model.

Bize P, Duran R, Fuchs K, Dormond O, Namur J, Decosterd LA, Jordan O, Doelker E, Denys A.

Radiology. 2016 Aug;280(2):425-35. doi: 10.1148/radiol.2016150361. Epub 2016 Feb 26.

PMID:
26919561
16.

DLL4 promotes continuous adult intestinal lacteal regeneration and dietary fat transport.

Bernier-Latmani J, Cisarovsky C, Demir CS, Bruand M, Jaquet M, Davanture S, Ragusa S, Siegert S, Dormond O, Benedito R, Radtke F, Luther SA, Petrova TV.

J Clin Invest. 2015 Nov 3;125(12):4572-86. doi: 10.1172/JCI82045.

17.

PI3K and AKT: Unfaithful Partners in Cancer.

Faes S, Dormond O.

Int J Mol Sci. 2015 Sep 3;16(9):21138-52. doi: 10.3390/ijms160921138. Review.

18.

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer.

Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Dallinga M, Shen L, Schlingemann RO, Pili R, Ho CM, Dyson PJ, van den Bergh H, Griffioen AW, Nowak-Sliwinska P.

Angiogenesis. 2015 Jul;18(3):233-44. doi: 10.1007/s10456-015-9462-9. Epub 2015 Apr 1.

19.

PGE2-induced colon cancer growth is mediated by mTORC1.

Dufour M, Faes S, Dormond-Meuwly A, Demartines N, Dormond O.

Biochem Biophys Res Commun. 2014 Sep 5;451(4):587-91. doi: 10.1016/j.bbrc.2014.08.032. Epub 2014 Aug 13.

PMID:
25128827
20.

Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance.

Singh AK, Arya RK, Maheshwari S, Singh A, Meena S, Pandey P, Dormond O, Datta D.

Int J Cancer. 2015 May 1;136(9):1991-2000. doi: 10.1002/ijc.28804. Epub 2014 Mar 4. Review.

Supplemental Content

Loading ...
Support Center